This Phase I, open-label, two-group, fixed-sequence study evaluated the pharmacokinetics and safety of AL-335, odalasvir, and simeprevir in healthy subjects. Group 1 (n = 16) received AL-335 800 mg once daily (QD) (days 1-3, 11-13, and 21-23), simeprevir 150 mg QD (days 4-23), and odalasvir 150 mg (day 14) followed by 50 mg QD (days 15-23). Group 2 (n = 16) received the same AL-335 regimen as in Group 1 plus odalasvir 150 mg (day 4) followed by 50 mg QD (days 5-23) and simeprevir 150 mg QD (days 14-23). Blood samples were collected to determine plasma concentrations of AL-335 (prodrug) and its metabolites, ALS-022399 (monophosphate precursor) and ALS-022227 (parent nucleoside), odalasvir, and simeprevir. Thirty-two subjects were enrolled. Odalasvir and simeprevir given alone, or in combination, increased AL-335 area under plasma concentration-time curve over 24 hours (AUC 0-24 h ) 3-, 4-, and 7-to 8-fold, respectively; ALS-022399 AUC 0-24 h increased 2-, 2-, and 3-fold, respectively. Simeprevir had no effect on ALS-022227 AUC 0-24 h , whereas odalasvir with/without simeprevir increased ALS-022227 AUC 0-24 h 1.5-fold. AL-335 had no effect on odalasvir or simeprevir pharmacokinetics. Odalasvir and simeprevir AUC 0-24 h increased 1.5-to 2-fold for both drugs when coadministered irrespective of AL-335 coadministration. Study medications were well tolerated with no serious adverse events. One subject prematurely discontinued study drugs (unrelated event). This study defined the preliminary pharmacokinetic and safety profiles of the combination of AL-335, odalasvir, and Abbreviations: AE, adverse event; ALT, alanine aminotransferase; ANOVA, analysis of variance; ANSM, French National Agency for the Safety of Medicine and Health Products; AST, aspartate aminotransferase; AUC0-24 h, area under plasma concentration-time curve over 24 hours; BCRP, breast cancer resistance protein; BMI, body mass index; CI, confidence interval; Cmax, maximum observed plasma concentration; C min , minimum observed plasma concentration; CPP, Comité de Protection des Personnes; CYP, cytochrome P450; DAA, direct-acting antiviral; DDI, drug-drug interaction; ECG, electrocardiogram; HCV, hepatitis C virus; LSM, least squares mean; NA, not applicable; OATP, organic anion-transporting polypeptide; ODV, odalasvir; PK, pharmacokinetic; QD, once daily; RNA, ribonucleic acid; SMV, simeprevir; SVR12, sustained virological response rates 12 weeks after the end of treatment; t 1/2 , apparent elimination half-life; TEAE, treatment-emergent adverse event; T last , time to last measurable plasma concentration; T max , time of the maximum observed plasma concentration; ULN, upper limit of normal. In recent studies evaluating 3-DAA regimens that include a nucleotide analog NS5B inhibitor (eg, sofosbuvir or dasabuvir), sustained virological response rates 12 weeks after the end of treatment (SVR12) were 80%-98% in treatment-na€ ıve patients with or without cirrhosis following 6 or 8 weeks of therapy 7-9,11 and 96%-98% in patients treated for 12-16 weeks who had previously failed on an NS5A-containing DAA regimen. 6,10 An 8-and 12-week 2-DAA regimen with glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor) has also been evaluated in treatment-na€ ıve or -experienced noncirrhotic genotype 1-infected patients demonstrating 99% and 100% SVR12 rates, respectively.
simeprevir in healthy subjects. These data support the further evaluation of this combination for the treatment of chronic hepatitis C virus infection.
K E Y W O R D S
AL-335, drug safety, drug-drug interactions, hepatitis C virus, odalasvir, pharmacokinetics, infection. This is associated with a spectrum of liver-related diseases ranging from mild inflammation to liver fibrosis, extrahepatic manifestations, and ultimately cirrhosis. HCV-related cirrhosis is associated with serious complications including hepatocellular carcinoma. 1, 2 Almost 400 000 patients die each year from complications of chronic HCV infection, with the majority of deaths attributable to cirrhosis and hepatocellular carcinoma. 1 Current treatment options for HCV infection comprise a combination of two or three oral, direct-acting antiviral (DAA) compounds. 3, 4 Evidence suggests that adding a third DAA with a different mechanism of action may increase efficacy and allow for a shorter treatment duration. [5] [6] [7] [8] [9] [10] In recent studies evaluating 3-DAA regimens that include a nucleotide analog NS5B inhibitor (eg, sofosbuvir or dasabuvir), sustained virological response rates 12 weeks after the end of treatment (SVR12) were 80%-98% in treatment-na€ ıve patients with or without cirrhosis following 6 or 8 weeks of therapy [7] [8] [9] 11 and 96%-98% in patients treated for 12-16 weeks who had previously failed on an NS5A-containing DAA regimen. 6 ,10 An 8-and 12-week 2-DAA regimen with glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor) has also been evaluated in treatment-na€ ıve or -experienced noncirrhotic genotype 1-infected patients demonstrating 99% and 100% SVR12 rates, respectively. 12 It has been suggested that the high SVR12 rates achieved with nucleotide-based 3-DAA regimens following a shortened treatment duration of 6 or 8 weeks may be partly ascribed to the more rapid first-phase decline in HCV ribonucleic acid (RNA) observed when a third DAA was added. 8 In addition to the high levels of therapeutic efficacy achieved with 2-or 3-DAA regimens, the opportunity to provide patients with an effective shorter course of therapy could also have a favorable impact on affordability, adherence, and patient quality of life due to reduced side effects and decreased pill burden. 8, 13, 14 Simeprevir is a HCV NS3/4A protease inhibitor licensed for the treatment of chronic HCV infection as a component of combination antiviral therapy. The recommended adult dose of simeprevir is 150 mg (100 mg in Japan) once daily (QD) administered with food.
Simeprevir is a substrate and inhibitor of P-glycoprotein, breast cancer resistance protein (BCRP), and organic anion-transporting polypeptide (OATP) 1B1/3, and is transported into the liver by OATP1B1/3 where it undergoes metabolism by cytochrome P450
(CYP) 3A. It is also a mild inhibitor of intestinal (not hepatic) CYP3A
and a mild but not clinically relevant inhibitor of CYP1A2. 15 Coadministration of simeprevir with cyclosporine, an inhibitor of multiple transporters such as OATP and P-glycoprotein, and with CYP3A inhibitors and inducers such as ritonavir and efavirenz, has resulted in clinically significant drug interactions such that coadministration of simeprevir with these drugs is not recommended. 15 Odalasvir is an investigational HCV NS5A inhibitor in develop- for the treatment of HCV infection. The effect of odalasvir and simeprevir on the pharmacokinetics of each other, and the effect of AL-335 and its metabolites on the pharmacokinetics of odalasvir and simeprevir were also evaluated. In addition, the safety and tolerability of the 2-and 3-DAA combination regimen was also assessed.
| MATERIAL AND METHODS

| Study design and subjects
This was an open-label, two-group, fixed-sequence study conducted at a single study center in Rennes, France (Biotrial). A two-group, fixed-sequence study design was chosen as this was deemed to be the most efficient way to evaluate the effect of simeprevir with/ without odalasvir on AL-335; and vice versa (Group 1) and the effect of odalasvir with/without simeprevir on AL-335; and vice versa (Group 2). Thus, this study design had the potential to gather both 2-way and 3-way DDIs. For both groups, the study consisted of a screening period, a study period, and two follow-up visits. The study design is shown in Figure 1 . All study treatments were administered on-site orally under fed conditions (a standard diet comprising 55% carbohydrates, 30% fat, and 15% protein;~2470 kcal on days where pharmacokinetic samples were taken). A visual check of the mouth was done to confirm study treatments were taken and swallowed. Subjects were assigned sequentially to Group 1 then to Group 2 after confirming eligibility.
The primary objective of the study was to assess the 2-and 3-way interaction between AL-335, odalasvir, and simeprevir in healthy subjects. A secondary objective was to determine the safety and tolerability of the DAAs alone and in combination.
| Study assessments
In both Groups 1 and 2, subjects were admitted to the clinic on day -1. Subjects remained in the clinic for the duration of the study with the exception of days 5-8 and days 15-18, where daily outpatient visits were performed. Subjects were discharged on day 24. The last study assessments were performed at the final follow-up visit 28 days after completion of the study confinement period.
| Bioanalysis and pharmacokinetic analysis
As this was an observational pharmacokinetic study, blood samples for pharmacokinetic analysis were collected predose and at 0.25, The subject that withdrew from the study on day 2, for reasons not related to the study, received two QD administrations of AL-335 800 mg alone (day 1 and day 2) before any PK samples were taken and was therefore excluded from the PK analysis was used to assess T max and a one-way ANOVA was used to assess steady-state on factor 'day'. Pharmacokinetic data were analyzed Safety analyses were performed on all subjects who received at least one dose of study drug, including those who did not complete the study.
Descriptive statistics of the safety findings were made using SAS â software version 9.3 (SAS Institute, Inc., Cary, NC, USA).
T A B L E 1 Subject baseline characteristics Unless otherwise stated, statistical tests for analyses were twosided at a 5% level of significance.
3 | RESULTS
| Subjects
A total of 54 subjects were screened; 22 subjects were not included due to screening failures. Thirty-two healthy subjects were screened and included in the study; of these, 29 (91%) completed the study and 3 (9%) discontinued prematurely ( Figure 2) . Two subjects in Group 1 discontinued due to reasons not related to the study; one withdrew from the study on day 2 and thus received two QD administrations of AL-335 800 mg alone (day 1 and day 2) before any pharmacokinetic samples were taken and was therefore excluded from the pharmacokinetic analysis; the other subject withdrew from the study on day 19 and was included in the pharmacokinetic analysis. The third subject from Group 2 discontinued treatment early on day 11 due to a tooth abscess and was included in the pharmacokinetic analysis.
All 32 subjects were included in the safety analysis population and 31 were included in the pharmacokinetic analysis.
Subject demographic and baseline disease characteristics are summarized in Table 1 . All 32 enrolled subjects (100%) were male, the majority were white (94%), mean age (AESD) was 39.0 AE 13.3 years, and mean body mass index (AESD) was 24.8 AE 3.8 kg/m 2 .
| Pharmacokinetics
Odalasvir and simeprevir, individually or in combination, had a marked effect on the pharmacokinetic profile of AL-335 and its metabolite ALS-022399, but less of an effect on ALS-022227 (Tables 2-4 odalasvir or simeprevir, and a 2.6-to 3.4-fold increase was noted when AL-335 was co administered with both odalasvir and simeprevir (Table 3 , Figure 3 ). No statistically significant difference in ALS-022399 T max was observed between any of the treatment combinations.
Simeprevir had no effect on ALS-022227 C max and AUC 0-24 h but increased C min 1.8-fold (Table 4 (Table 5) . No clinically relevant difference in simeprevir T max was observed when simeprevir was coadministered with odalasvir. Coadministration of simeprevir with or without AL-335 increased odalasvir C max , AUC 0-24 h , and C min by 1.3-fold, 1.5-to 1.6-fold, and 1.9-to 2.1-fold, respectively (Table 6 ). In Group 2, a statistically significant difference in odalasvir T max was observed between simeprevir coadministered with odalasvir (median T max 7.00; range 3.0-9.0) versus odalasvir alone (median T max 5.00; range: 5.0-7.0) (P = .0116) and with coadministration of AL-335, odalasvir, and simeprevir (median T max 6.00; range: 5.0-16.0) versus odalasvir alone (median T max 5.00; range: 5.0-7.0) (P = .0176); no statistically significant difference in odalasvir T max was observed between AL-335 coadministered with odalasvir versus odalasvir alone.
| Safety
A total of 20 treatment-emergent AEs (TEAEs) were reported in 12 subjects (37.5%) ( Table 7) . None of these TEAEs were considered serious. One TEAE (tooth abscess) led to premature study-drug discontinuation, due to a need for antibiotics which were considered a possible risk for additional DDI; the event was considered unrelated to study drugs. All TEAEs were mild (n = 14) or moderate (n = 6; oropharyngeal pain, tooth abscess, increase in levels of alanine aminotransferase 10 days in Group 1) cannot be ruled out as a possible etiology to the different rates observed. Importantly, no fatigue event was considered to be clinically significant in this study as they were not associated with other abnormalities, premature study-drug discontinuation or other medical interventions.
TEAEs were more common in Group 2 than in Group 1 (5 TEAEs in 3 subjects in Group 1 and 15 TEAEs in 9 subjects in Group 2), with the major difference being the incidence of fatigue (1 vs. 7 events in Groups 1 and 2, respectively). After excluding this term, the incidence of TEAEs across the two groups was comparable (4 vs.
8 TEAEs in Groups 1 and 2, respectively). Despite the numeric difference in incidence of TEAEs across the two groups, none of the events in either group appear to have been clinically concerning as evidenced by a lack of severe events or requirement of treatment discontinuation (with the exception of the subject that discontinued study treatment due to a tooth abscess).
Only two of the 20 TEAEs reported, oropharyngeal pain and tooth abscess, required concomitant treatment.
One study subject experienced clinically significant laboratory elevations in serum alanine aminotransferase (peak 5.5 9 ULN; grade 3) and aspartate aminotransferase (peak 3.8 9 ULN; grade 2) from day 26 to day 36, which were considered to be attributable to the onset of a new cytomegalovirus infection (diagnosed by changes in immunoglobulin M and immunoglobulin G values) and not to any of the three study drugs. No other clinically significant changes were observed with respect to laboratory safety parameters (including hematology, blood chemistry, coagulation, and urinalysis parameters), vital signs, physical examination, or ECGs.
| DISCUSSION
The aim of this study was to investigate potential DDIs between AL-335, odalasvir, and simeprevir in healthy subjects in order to increase our understanding of the pharmacokinetics and safety of the combination, and to guide dose selection of the individual components for the development of a 2-or 3-DAA combination regimen for the treatment of HCV.
Odalasvir and simeprevir, when administered independently and in combination, had a marked effect on AL-335 and ALS- Odalasvir and simeprevir statistically significantly affected the pharmacokinetics of each other, producing an approximate 1.5-to 2-fold increase in exposure (C max , C min , AUC 0-24 h ) for both drugs. Odalasvir is a weak OATP1B1 substrate in vitro and simeprevir is a clinically confirmed OATP1B1 inhibitor at 150 mg QD. Simeprevir is a P-glycoprotein substrate and odalasvir is a P-glycoprotein inhibitor in vitro. These mechanisms may have contributed to the observed increases in odalasvir and simeprevir exposure.
Despite observing higher exposures than expected, the 2-DAA and 3-DAA regimens were well tolerated during the short duration of treatment. The only noteworthy TEAE observed was an excess of fatigue events in Group 2 versus Group 1, which does not appear to be clinically concerning (i.e., it did not result in discontinuation of study drugs or otherwise require medical intervention) and is presumed to be related to chance. The only other noteworthy safety finding was the Grade 3 elevation of alanine aminotransferase/aspartate aminotransferase in a subject which occurred concurrent to seroconversion for cytomegalovirus. This is considered likely attribu- Evaluation of the mean t 1/2 was performed on day 23 only, when enough detectable time points during the elimination phase were available.
An important strength of the study was its design, which allowed for the assessment of complex 2-and 3-way drug interactions between AL-335, odalasvir, and simeprevir. A limitation of the study is that we were unable to evaluate any potential impact on the active entity of AL-335, nucleoside triphosphate, as this is only present intracellularly. Thus, how any change in plasma kinetics of the AL-335 analytes may translate to the modulation of liver nucleoside triphosphate remains unknown. The effect of the DDI on viral-load reduction can only be evaluated when this DAA combination is evaluated in patients. In addition, differences in metabolism and transporter expression between healthy volunteers and HCVinfected patients may limit extrapolation of results. 21 Another limitation is that the effect of simeprevir on the pharmacokinetics of odalasvir was estimated without taking into account odalasvir accumulation over time; therefore, the data presented assume steadystate of odalasvir. This can be corrected for by comparing data between Groups 1 and 2 after 7 days of treatment with odalasvir.
When the difference in odalasvir treatment duration is accounted for, the effect of simeprevir on odalasvir is reduced with a 10-15% C max increase and 12-19% AUC increase until day 17, compared with a 25% and 50% increase, respectively, at day 20 without accounting for this difference.
The data from this study were used to guide the initial dose selection in Phase IIa and Phase IIb studies. The Phase IIa study, AL-335-604 (NCT02569710), is an ongoing study assessing the safety, pharmacokinetics, and efficacy of a 2-and 3-DAA regimen comprising AL-335 in combination with odalasvir with or without simeprevir in HCV-infected patients. 22 The Phase IIb study, OMEGA-1 (ClinicalTrials.gov ID: NCT02765490), is evaluating AL-335, odalasvir, and simeprevir for 6 and 8 weeks' treatment duration in HCV genotype 1-, 2-, 4-, 5-, and 6-infected patients without cirrhosis. 23 In conclusion, in this study, combinations of AL-335, odalasvir, and simeprevir were found to be well tolerated in healthy subjects despite the observed higher exposures of all drugs, in particular AL-335. These findings have helped to refine the dose selection of each component to establish a regimen for evaluation in Phase II studies in patients with chronic HCV infection.
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